Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) reported on Friday that full results from the Phase III KALOS and LOGOS trials, published in The Lancet Respiratory Medicine, show that AstraZeneca's BREZTRI Aerosphere delivered statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) therapies, including Symbicort and PT009, as well as the combined ICS/LABA treatment groups.

BREZTRI is a single-inhaler, fixed-dose triple combination of ICS/LABA and a long-acting muscarinic antagonist.

In a pre-specified pooled analysis of primary endpoints across both trials, BREZTRI improved lung function by 76 mL in morning pre-dose trough FEV1 and by 90 mL in FEV1 AUC0-3 over 24 weeks versus dual therapy, with both measures achieving unadjusted p